In March 2007, a group of community activists, many living with HIV and hepatitis C virus (HCV), gathered with researchers, doctors, regulators, and representatives from Abbott, Roche, Schering, and Tibotec, in Sitges, Spain, at a meeting held by the European…
Excerpts from the FDA Hearings By Bob Huff There are a large number of experimental drugs now being developed to treat hepatitis C virus (HCV) infection. A race is on to find new HCV drugs because millions of people may…
Growing Chasm Between Bench and Bedside By Tracy Swan Hepatitis C virus (HCV) and HIV/HCV coinfection were prominently featured at this year's Retrovirus conference. Coverage ranged from scientific progress in the laboratory to treatment access in the clinic. During the…
TB, HIV and Viral Hepatitis By Tracy Swan Disturbing reports of overlapping TB, HIV, and viral hepatitis epidemics emerged at the 2005 International AIDS Society Conference. In the newly independent states of Eastern Europe and Central Asia, HIV incidence continues…
Brown University Clinician Leads the Way in Providing Competent Care to Coinfected Injectors By Tracy Swan Directly Observed Peg-IFN? A majority of the estimated 4 million hepatitis C virus (HCV) infections in the United States result from injection drug use…
Expert Panel's Decision to Recommend Against Routine HCV Screening Draws Community Ire By Tracy Swan "Inconsistent With Other Bodies" In March of 2004, the U.S. Prevention Services Task Force's "Screening for Hepatitis C Virus Infection in Adults: Recommendation Statement" was…
XI CROI, Stage for Results of Three Large HCV Treatment Trials By Tracy Swan Still No Head-to-Head Eagerly awaited results from three pivotal safety and efficacy studies of HCV treatment in HIV/HCV coinfected individuals were presented at the 11th Conference…
Proliferation of Polymerase Inhibitors and Other Tales From the HCV Crypt By Tracy Swan Building a Better Ribavirin Liver disease has become increasingly prominent in the HAART era. Hepatitis C progresses more rapidly in HIV-positive people, and is more difficult…
by Rob Camp January: starts as new TAG's Antiviral Project Director. Rob and Mark to Houston for ATAC structure meeting to develop stronger national coalition, then to D.C. for Federal AIDS Policy Partnership meeting. Talk of coming assault on Medicaid…
Expediency, Cost-Cutting Trump Science in Peg-Intron Clinical Development Plan By Tracy Swan The Head-to-Head That Wasn't In October of 2003, Schering-Plough held a meeting with HCV and HIV/HCV advocates where they announced a "new" Schering -- one that prioritizes earning…